FDA accepts Supplemental BLA and EMA Validates Application for Opdivo as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma March 15, 2023
Kinnate Biopharma Acquires Ownership Stake from Kinnjiu Biopharma; Initiates Ph 1 Trial for Exarafenib (KIN-2787) in China February 28, 2023
mRNA-4157/V940 + KEYTRUDA® combo Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Complete Resection February 28, 2023
BLA submitted to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma January 11, 2023
Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs December 19, 2022
mRNA-4157/V940 + KEYTRUDA® (pembrolizumab) Met Primary Efficacy Endpoint in Ph 2b KEYNOTE-942 Trial December 19, 2022
Ph 1 Trial of E6201 + Dabrafenib initiated in Patients with CNS Metastases from BRAF V600 Mutated Metastatic Melanoma December 5, 2022
IO Biotech and Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 With KEYTRUDA in Ph 2 Trial in Patients with Resectable Tumors November 16, 2022
Eucure Biopharma Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence November 16, 2022
Voluntary Pause of Enrollment in Ongoing in ITIL-168 and ITIL-306 Trials Related to Manufacturing November 16, 2022
Data from CheckMate -76K Shows that Opdivo Reduced the Risk of Recurrence or Death by 58% vs. Placebo in Patients with Completely Resected Stage IIB/C Melanoma October 26, 2022
Adjuvant Treatment with Opdivo Demonstrated Statistically Significant Improvement in RFS in Patients with Stage IIB/C Melanoma in the CheckMate-76K Trial September 28, 2022
European Commission approves Opdualag (nivolumab + relatlimab) for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1% September 28, 2022
Positive data announced from multiple expansion cohorts of Ph 1 trial of fianlimab and Libtayo® (cemiplimab) in advanced melanoma September 13, 2022
Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable CSCC Published in NEJM September 13, 2022
Enrollment initiated in Ph 2 Trial of Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma September 7, 2022
Ph 2 SCOPE trial of SCIB1 vaccine in metastatic melanoma patients expanded; additional cohort to test SCIB1 vaccine in combination with checkpoint doublet therapy June 16, 2022
